Cencora (COR) Q4 FY2026 Earnings Call: Q&A Summary

Q: Elizabeth Anderson from Evercore ISI asked why resegmenting the business makes sense at this point and what it provides that the old setup did not.

A: Robert Mauch, President and CEO, explained that the change is driven by the rapid growth of biologics and specialty products. He stated it enhances operational execution, brings the company closer to customers, and provides increased visibility for shareholders.

Q: Lisa Gill from JPMorgan asked about the organic growth rate in specialty for next year and potential impacts from reimbursement and the recent election.

A: Robert Mauch, President and CEO, noted that Cencora has a long history of advocacy and education across multiple administrations and is well positioned to advise on policy changes. Eva Boratto, CFO, added that specialty operating income growth is expected to be 18% to 21%, with underlying growth in line with the mid-teens algorithm excluding the One Oncology wraparound.

Q: Glen Santangelo from Barclays asked if volumes are the primary driver of the mid-teens specialty growth rate and for puts and takes on margins given biosimilar conversions.

A: Eva Boratto, CFO, responded that the long-term algorithm reflects fast-paced market growth and continued growth at MSOs through organic physician acquisition and tuck-in M&A.

Q: Charles Rhyee from TD Cowen asked how management incorporates the upcoming cycle of small molecule generics into long-term segment growth assumptions.

A: Robert Mauch, President and CEO, stated that both small molecule generics and biosimilars are contemplated in guidance and are positive for Cencora, noting that Part B biosimilars and oral generics provide good margins and revenue impacts.

Q: Allen Lutz from Bank of America asked about synergies between global clinical trials and MSOs, and whether capital deployment strategy evolves with the resegmentation.

A: Robert Mauch, President and CEO, clarified that the primary thesis is growth and connecting capabilities from manufacturer to provider rather than financial synergies. Eva Boratto, CFO, confirmed there is no change in the capital allocation strategy, which focuses on internal investments, strategic M&A, share repurchases, and a growing dividend.

Q: Eric Percher from Nephron Research asked about the factors impacting top line versus operating profit headwinds in pharmaceutical distribution and services for 2027.

A: Eva Boratto, CFO, explained that operating income growth of 2% to 4% includes a customer volume shift wraparound and an approximate 1 percentage point FX impact, while consolidated revenue is affected by the Pro Forma divestiture and the Covetrus merger.

Q: Erin Wilson Wright from Morgan Stanley asked if infusion space assets like Option Care are of interest and if Cencora is entertaining ideas outside of oncology and retina.

A: Robert Mauch, President and CEO, stated that the pharmaceutical-centric strategy keeps MSO expansion focused on oncology and retina. He noted that while Cencora supports infusion customers across its portfolio, owning that capability is not required.

Q: George Hill from Deutsche Bank asked for a dollar percentage breakdown of the MSO contribution versus wholesaling and GPO, and the target margin profile for the specialty segment.

A: Eva Boratto, CFO, stated that MSOs represented about 10% of consolidated operating income in 2026, and noted that specialty carries a higher margin profile encompassing World Courier, 3PL, MSOs, and consulting businesses.

Q: Eric Coldwell from Baird asked for framing on the elevated CapEx target of $1 billion and whether it represents a permanent higher base or a temporary spike.

A: Eva Boratto, CFO, explained that the dollar spend is elevated due to investments in U.S. supply chain infrastructure, digital transformation, SAP, and MSOs, aligning as a percentage of gross profit with historical periods of significant infrastructure investment.

Q: Kevin Caliendo from UBS asked about One Oncology profitability run rates, potential impacts from Cigna's new wholesale business, and the Option Care relationship.

A: Eva Boratto, CFO, stated that One Oncology and RCA continue to perform well, and noted that Option Care impacts would move within the distribution segment guidance range. Robert Mauch added that all customer relationships are contemplated in fiscal 2027 guidance.